Dybly AG

Swiss Biotech Association

Not a member

Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation).

http://www.dybly.com

Location

Bäumleingasse 18, 4051 Basel

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2007
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Alloy Therapeutics (Switzerland) AG

Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.
Allschwil

Member

Peptone Switzerland AG

Peptone, founded in 2018, specialises in the development of novel therapeutics against Intrinsically disordered proteins (IDP) for cancer and inflammatory diseases, to name a few. Peptone's approach stems from experimental biophysics, supercomputing, and machine learning.
6500 Bellinzona

Member

plusbiome AG

plusbiome AG is a Swiss startup company working at the interface of digital health and the microbiome. We design and market customised probiotics that truly support customers and their well-being,. Customers also profit from accompanying Apps.
4057 Basel

Member